-
Product Insights
Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency – Drugs In Development, 2023
Global Markets Direct’s, ‘Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency - Drugs In Development, 2023’, provides an overview of the Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency pipeline landscape. The report provides comprehensive information on the therapeutics under development for Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Friedreich Ataxia – Drugs In Development, 2023
Global Markets Direct’s, ‘Friedreich Ataxia - Drugs In Development, 2023’, provides an overview of the Friedreich Ataxia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Friedreich Ataxia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Senex Energy – Lacerta Coal Seam Gas Field Development – Queensland
Equip yourself with the essential tools needed to make informed and profitable decisions with our Senex Energy - Lacerta Coal Seam Gas Field Development - Queensland report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alpha N-acetylglucosaminidase Pipeline Products Market Report Overview Alpha N-acetylglucosaminidase is a protein associated with Sanfilippo syndrome. This enzyme is located in lysosome compartments within cells that digest and recycle different types of molecules. Alpha N-acetylglucosaminidase is involved in the stepwise breakdown of large molecules called glycosaminoglycans (GAGs). Alpha N-acetylglucosaminidase removes a sugar called N-acetylglucosamine when it is at the end of the GAG chain. The Alpha N-Acetylglucosaminidase pipeline market research report provides comprehensive information on the therapeutics under development for...
-
Product Insights
Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glioblastoma Multiforme Pipeline Drugs Market Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness, and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy, and chemotherapy. The Glioblastoma Multiforme (GBM) drugs in development market research report provides comprehensive information on the therapeutics under...
-
Product Insights
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Mucopolysaccharidosis type III (MPS III) is also known as Sanfilippo syndrome. It is an inherited metabolic disease caused by the absence or malfunctioning of certain enzymes needed to break down molecules called glycosaminoglycans (GAG). Symptoms include seizures, hyperactivity, liver and spleen enlargement, severe diarrhea or constipation, and enlargement of tonsils and adenoids. Treatment includes enzyme replacement therapy (ERT). The MPS III pipeline market research report provides comprehensive information on the therapeutics under development for MPS III, complete with analysis by...
-
Product Insights
Friedreich Ataxia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Friedreich Ataxia Drugs in Development Report Overview Friedreich’s ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Its signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties, and diabetes. The Friedreich Ataxia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Friedreich Ataxia, complete with analysis...
-
Product Insights
Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Frataxin is a protein encoded by the FXN gene. It promotes the biosynthesis of heme and assembly and repair of iron-sulfur clusters by delivering Fe2+ to proteins involved in these pathways. It plays a role in the protection against iron-catalyzed oxidative stress through its ability to catalyze the oxidation of Fe2+ to Fe3. The Frataxin Mitochondrial - Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Frataxin Mitochondrial, complete with analysis by stage of...